Executives On The Move: Operations Change At Khondrion And A Promotion At Grunenthal
Khondrion BV, developer of therapies for mitochondrial disease, has appointed a former Novartis SVP as COO, and pain and inflammation medicines firm Grunenthal GmbH to promote acting CSO to CSO and director. Also, Royal DSM NV says CEO to resign in February.
You may also be interested in...
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A Roche director joins predictive drug discovery firm Compugen and a Bristol-Myers Squibb exec is welcomed at immuno-oncology company Turnstone Biologics – both in Business Development. And China- and US-based biopharma Antegene brings on Celgene manager as CBO.